Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations

Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations

Abstract Breast cancer (BC) is a heterogeneous disease that is the most common cancer in women worldwide. However, precise subtyping and corresponding treatments have improved patient outcomes. Hormone receptor (HR)-positive, human epidermal growth factor receptor type 2 (HER2)-negative (HR+/HER2-)...

Full description

Bibliographic Details
Main Authors: Shunchao Yan, Murshid Imam
Format: Article
Language:English
Published: Springer 2023-06-01
Series:Discover Oncology
Subjects:
Breast cancer
BRCA mutation
Cancer treatment
PARP inhibitor
Hormone receptor-positive
Online Access:https://doi.org/10.1007/s12672-023-00732-0

Internet

https://doi.org/10.1007/s12672-023-00732-0

Similar Items